There are currently several reputable guidelines on the treatment of actinic keratosis (AK) from groups in Canada, the United Kingdom, and Europe. These recommendations, based on evidence or expert consensus, offer clinicians a variety of treatment options for the different clinical presentations of AKs. Although the guidelines are similar in some regards, variations exist in treatment options, duration, and strength of recommendation. Some guidelines also lack input on specific therapies and certain types of AK, such as hypertrophic or thin presentations. The purpose of this article is to review and compare guidelines published by Canadian, UK, and European groups for the management of AKs in patients.
PoulinYLyndeCWBarberKet al. Non-melanoma skin cancer in Canada chapter 3: management of actinic keratoses. J Cutan Med Surg. 2015;19(3):227-238.
2.
StockflethE.The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol. 2012;11(12):1462-1467.
3.
CostaCScalvenziMAyalaFFabbrociniGMonfrecolaG.How to treat actinic keratosis? An update. J Dermatol Case Rep. 2015;9(2):29-35.
4.
ChettyPChoiFMitchellT.Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb). 2015;5(1):19-35.
5.
De BerkerDMcGregorJMMohd MustapaMFExtonLSHughesBR.British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis2017. Br J Dermatol. 2017;176(1):20-43.
6.
SchmittARBordeauxJS.Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol. 2013;31(6):712-717.
7.
KirbyJSScharnitzTSeiverlingE VAhrnsHFergusonS.Actinic keratosis clinical practice guidelines: an appraisal of quality. Dermatol Res Pract. 2015;2015:456071.
8.
WernerRNStockflethEConnollySMet al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis—International League of Dermatological Societies in cooperation with the European Dermatology Forum–Short version. J Eur Acad Dermatology Venereol. 2015;29(11):2069-2079.
9.
ChiarelloSE.Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000;26(8):728-732.
10.
VatveMOrtonneJPBirch-MachinMAGuptaG.Management of field change in actinic keratosis. Br J Dermatol. 2007;157(suppl 2):21-24.
11.
DeonizioJMDMulinari-BrennerFA.Cryopeeling for treatment of photodamage and actinic keratosis: liquid nitrogen versus portable system. An Bras Dermatol. 2011;86(3):440-444.
12.
CeilleyRIJorizzoJL.Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(1)(suppl 1):S28-S38.
13.
PariserDLossRJarrattMet al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2008;59(4):569-576.
14.
PiacquadioDJChenDMFarberHFet al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp. Arch Dermatol. 2004;140:41.
15.
SzeimiesRMMathesonRTDavisSAet al. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg. 2009;35(4):586-592.
16.
DirschkaTRadnyPDominicusRet al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol. 2012;166(1):137-146.
17.
PariserDMLoweNJStewartDMet al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48(2)(suppl):227-232.
18.
MoloneyFJCollinsP.Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol. 2007;157(1):87-91.
19.
BraathenLRSzeimiesRMBasset-SeguinNet al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol2007;56(1):125-143.
20.
ScolaNTerrasSGeorgasDet al. A randomized, half-side comparative study of aminolaevulinate photodynamic therapy vs. CO2 laser ablation in immunocompetent patients with multiple actinic keratoses. Br J Dermatol. 2012;167(6):1366-1373.
21.
Togsverd-BoKHaakCSThaysen-PetersenDet al. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial. Br J Dermatol. 2012;166(6):1262-1269.
22.
WitheilerDDLawrenceNCoxSECruzCCockerellCJFreemenRG.Long-term efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23(3):191-196.
23.
ColemanWPYarboroughJMMandySH.Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg. 1996;22(1):17-21.
24.
AskewDAMickanSMSoyerHPWilkinsonD.Effectiveness of 5-fluorouracil treatment for actinic keratosis: a systematic review of randomized controlled trials. Int J Dermatol. 2009;48(5):453-463.
25.
GuptaAKDaveyVMcPhailHHartDA.Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9(5):209-214.
26.
HankeCWBeerKRStockflethEWuJRosenTLevyS.Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62(4):573-581.
27.
SzeimiesRMGerritsenMJPGuptaGet al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51(4):547-555.
28.
LebwohlMSwansonNAndersonLLMelgaardAXuZBermanB.Supplement to: Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019.
29.
AlomarABichelJMcRaeS.Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157(1):133-141.
30.
JorizzoJDinehartSMathesonRet al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57(2):265-268.
31.
KormanNMoyRLingMet al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis. Arch Dermatol. 2005;141(4):467-473.
32.
GebauerKShumackSCowenPSJ. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol. 2009;161(4):897-903.
33.
LebwohlMDinehartSWhitingDet al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50(5):714-721.
34.
SillerGGebauerKWelburnPKatsamasJOgbourneSM.PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16-22.
35.
AndersonLSchmiederGJWerschlerWPet al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60(6):934-943.
36.
WolfJEJTaylorJRTschenEKangS. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40(11):709-713.
37.
SimonJCDominicusRKarlLRodríguezRWillersCDirschkaT. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatology Venereol. 2015;29(5):881-889.
38.
JirakulapornTEndrizziBLindgrenBMathewJLeePKDudekAZ.Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant. 2011;25(4):541-548.
39.
ChettyPChoiFMitchellT.Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb). 2015;5(1):19-35.
40.
ChenACMartinAJChoyBet al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618-1626.
